227 related articles for article (PubMed ID: 30198305)
1. Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant.
Keks NA; Hope J; Keogh S; Copolov DL
Australas Psychiatry; 2018 Oct; 26(5):537-540. PubMed ID: 30198305
[TBL] [Abstract][Full Text] [Related]
2. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
3. Milnacipran: beyond a role of antidepressant.
Pae CU; Marks DM; Shah M; Han C; Ham BJ; Patkar AA; Masand PS
Clin Neuropharmacol; 2009; 32(6):355-63. PubMed ID: 19620845
[TBL] [Abstract][Full Text] [Related]
4. [Between depression and fibroniyalgia: the fate of the antidepressant].
Drobizhev MY; Fedotova AV; Kikta SV; Antokhin EY
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(4):114-120. PubMed ID: 27386594
[TBL] [Abstract][Full Text] [Related]
5. Serotonin noradrenaline reuptake inhibitors: Logical evolution of antidepressant development.
Montgomery S
Int J Psychiatry Clin Pract; 2006; 10 Suppl 2():5-11. PubMed ID: 24921676
[TBL] [Abstract][Full Text] [Related]
6. Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium.
Bernstein CD; Albrecht KL; Marcus DA
Expert Opin Pharmacother; 2013 May; 14(7):905-16. PubMed ID: 23506481
[TBL] [Abstract][Full Text] [Related]
7. Chronopharmacological Analysis of Antidepressant Activity of a Dual-Action Serotonin Noradrenaline Reuptake Inhibitor (SNRI), Milnacipran, in Rats.
Kawai H; Machida M; Ishibashi T; Kudo N; Kawashima Y; Mitsumoto A
Biol Pharm Bull; 2018; 41(2):213-219. PubMed ID: 29386481
[TBL] [Abstract][Full Text] [Related]
8. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia.
Vitton O; Gendreau M; Gendreau J; Kranzler J; Rao SG
Hum Psychopharmacol; 2004 Oct; 19 Suppl 1():S27-35. PubMed ID: 15378666
[TBL] [Abstract][Full Text] [Related]
9. An open-label clinical trial of milnacipran in fibromyalgia syndrome with co-morbid depressive symptoms.
Nagaoka S; Ohno M; Sekiguchi A
Int J Psychiatry Clin Pract; 2004; 8(1):47-51. PubMed ID: 24937583
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.
Clerc G;
Int Clin Psychopharmacol; 2001 May; 16(3):145-51. PubMed ID: 11354236
[TBL] [Abstract][Full Text] [Related]
11. Milnacipran for treatment of fibromyalgia.
Kyle JA; Dugan BD; Testerman KK
Ann Pharmacother; 2010 Sep; 44(9):1422-9. PubMed ID: 20716692
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
Iyengar S; Webster AA; Hemrick-Luecke SK; Xu JY; Simmons RM
J Pharmacol Exp Ther; 2004 Nov; 311(2):576-84. PubMed ID: 15254142
[TBL] [Abstract][Full Text] [Related]
13. Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors.
Mease PJ
Am J Med; 2009 Dec; 122(12 Suppl):S44-55. PubMed ID: 19962496
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the analgesic effects of ammoxetine, a novel potent serotonin and norepinephrine reuptake inhibitor.
Zhang TT; Xue R; Zhu L; Li J; Fan QY; Zhong BH; Li YF; Ye CY; Zhang YZ
Acta Pharmacol Sin; 2016 Sep; 37(9):1154-65. PubMed ID: 27424654
[TBL] [Abstract][Full Text] [Related]
15. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial.
Matthey A; Cedraschi C; Piguet V; Besson M; Chabert J; Daali Y; Courvoisier D; Montagne A; Dayer P; Desmeules JA
Pain Physician; 2013; 16(5):E553-62. PubMed ID: 24077206
[TBL] [Abstract][Full Text] [Related]
16. Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia.
Palmer RH; Periclou A; Banerjee P
Ther Adv Musculoskelet Dis; 2010 Aug; 2(4):201-20. PubMed ID: 22870448
[TBL] [Abstract][Full Text] [Related]
17. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.
Fava GA; Benasi G; Lucente M; Offidani E; Cosci F; Guidi J
Psychother Psychosom; 2018; 87(4):195-203. PubMed ID: 30016772
[TBL] [Abstract][Full Text] [Related]
18. Milnacipran affects mouse impulsive, aggressive, and depressive-like behaviors in a distinct dose-dependent manner.
Tsutsui-Kimura I; Ohmura Y; Yoshida T; Yoshioka M
J Pharmacol Sci; 2017 Jul; 134(3):181-189. PubMed ID: 28694090
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of milnacipran by risperidone in treatment for major depression.
Tani K; Takei N; Kawai M; Suzuki K; Sekine Y; Toyoda T; Minabe Y; Mori N
Int J Neuropsychopharmacol; 2004 Mar; 7(1):55-8. PubMed ID: 14731310
[TBL] [Abstract][Full Text] [Related]
20. A probable case of movement disorder (Tardive dyskinesia) due to duloxetine treatment.
Yılmaz R; Üstün D; Tuncer Uzun S; Reisli R; Türk Ş
Agri; 2018 Oct; 30(4):199-201. PubMed ID: 30403275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
